{
    "clinical_study": {
        "@rank": "36631", 
        "arm_group": [
            {
                "arm_group_label": "NPH and insulin lispro", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients diagnosed with diabetes during pregnancy will be randomized to long acting insulin NPH and short acting insulin lispro in a basal bolus regimen to treat post prandial hyperglycemia using a dosing schedule of 50% NPH calculated by the patients weight and gestational age and 50% lispro pending their last three SMPG average."
            }, 
            {
                "arm_group_label": "NPH and insulin glulisine", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients with a diagnosis of diabetes during pregnancy will be randomized to using long acting insulin NPH and short acting insulin glulisine as treatment for post prandial hyperglycemia with a 50% NPH dosing schedule based on the weight and gestational age and 50% glulisine schedule based on their last three SMBG result average."
            }
        ], 
        "brief_summary": {
            "textblock": "We hypothesize that insulin glulisine is non-inferior to currently proven rapid-acting\n      insulin lispro when used in a basal/bolus regimen to treat hyperglycemia in patients with\n      gestational diabetes mellitus."
        }, 
        "brief_title": "Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes During Pregnancy", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes, Gestational"
            ]
        }, 
        "detailed_description": {
            "textblock": "To date, only two rapid-acting insulin analogs have been shown to be safe and effective for\n      the treatment of diabetes during pregnancy: insulin aspart and insulin lispro.\n\n      The pharmacokinetics and pharmacodynamics of insulin glulisine are unique and insulin\n      glulisine may be the best rapid-acting analog for the treatment of post-prandial\n      hyperglycemia. We believe that insulin glulisine should be evaluated in women with\n      gestational diabetes for its potential efficacy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed Consent to participate in clinical trial\n\n          -  Pregnant and 20-30 weeks gestation\n\n          -  Diagnosed with gestational diabetes\n\n          -  Failed diet therapy (failed lifestyle modification will be defined as 10% or greater\n             SMBG values above pre-meal <90mg/dL and post prandial < 120mg/dL\n\n          -  Eat at least 2 meals per day\n\n        Exclusion Criteria:\n\n          -  Pregnant women <18 years old\n\n          -  Blood pressure > 140/80 mmHg\n\n          -  A1C equal to or greater than 6.5% at time of enrollment\n\n          -  Pre-pregnancy BMI > 40Kg/m squared\n\n          -  Evidence of any fetal anomaly on any fetal ultrasound\n\n          -  Currently using hypoglycemic agent\n\n          -  Refusal to use insulin before meals\n\n          -  Inability to understand instructions or to consent to participate\n\n          -  Pregnant women with history of T1DM or T2DM\n\n          -  Clinical judgment by investigator that patient is inappropriate for clinical trial or\n             has a metabolic disorder that could interfere with results"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01662921", 
            "org_study_id": "APIDRL06229"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "NPH and insulin lispro", 
                    "NPH and insulin glulisine"
                ], 
                "description": "Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age", 
                "intervention_name": "NPH", 
                "intervention_type": "Drug", 
                "other_name": "Humulin N, Novolin N"
            }, 
            {
                "arm_group_label": "NPH and insulin lispro", 
                "description": "Insulin lispro dosing will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days", 
                "intervention_name": "Insulin LISPRO", 
                "intervention_type": "Drug", 
                "other_name": "Humalog"
            }, 
            {
                "arm_group_label": "NPH and insulin glulisine", 
                "description": "Insulin glulisine will be titrated weekly based on the patient's average SMBG  readings from each meal during the past three days", 
                "intervention_name": "Insulin glulisine", 
                "intervention_type": "Drug", 
                "other_name": "Apidra"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin LISPRO", 
                "Insulin glulisine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "bolus treatment", 
        "lastchanged_date": "December 3, 2013", 
        "link": {
            "description": "Web page for Sansum Diabetes Research Institute", 
            "url": "http://www.sansum.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Santa Barbara", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "93105"
                }, 
                "name": "Sansum Diabetes Research Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Lois Jovanovic, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Kristin Castorino, DO", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Non-inferiority Trial Comparing Insulin Glulisine to Insulin Lispro as Part of a Basal-bolus Insulin Regimen for the Treatment of Gestational Diabetes.", 
        "other_outcome": [
            {
                "measure": "Compare incidence of birth weight >90th percentile", 
                "safety_issue": "No", 
                "time_frame": "delivery"
            }, 
            {
                "measure": "Compare incidence of primary cesarean section", 
                "safety_issue": "No", 
                "time_frame": "delivery"
            }
        ], 
        "overall_contact": {
            "email": "ljovanovic@sansum.org", 
            "last_name": "Lois Jovanovic, MD", 
            "phone": "805-682-7638"
        }, 
        "overall_contact_backup": {
            "email": "kcastorino@sansum.org", 
            "last_name": "Kristin Castorino, DO", 
            "phone": "805-682-7638"
        }, 
        "overall_official": [
            {
                "affiliation": "Sansum Diabetes Research Institute", 
                "last_name": "Lois Jovanovic, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Sansum Diabetes Research Institute", 
                "last_name": "Kristin Castorino, DO", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "compare average 1-hour post prandial SMBG measurements between patients randomized to insulin glulisine or insulin lispro", 
            "measure": "show that insulin glulisine is non-inferior to insulin lispro in a basal/bolus regimen to treat hyperglycemia in patient with gestational diabetes mellitus", 
            "safety_issue": "No", 
            "time_frame": "week 4 of insulin treatment"
        }, 
        "reference": [
            {
                "PMID": "17596476", 
                "citation": "Jovanovic L, Pettitt DJ. Treatment with insulin and its analogs in pregnancies complicated by diabetes. Diabetes Care. 2007 Jul;30 Suppl 2:S220-4. Review. Erratum in: Diabetes Care. 2007 Dec;30(12):3154."
            }, 
            {
                "citation": "7. Arnolds S, Rave K, Hovelmann U, Fischer A, Sert-Langeron C, Heise T: Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. Exp Clin Endocrinol Diabetes 2010; 118(9):662-664."
            }, 
            {
                "citation": "9. Manderson JG, Patterson CC, Hadden DR, Traub Al, Ennis C, McCance DR. Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet gynecol 189(2):507 512, 2003.Jovanovic L, Druzin M, Peterson CM. The effect of euglycemia on the outcome of pregnancy in insulin-dependent diabetics as compared to normal controls. Am J Med. 71:921-927, 1981"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01662921"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "patients will come to the study site under fasting conditions and eat a standardized meal in the morning post administration of insulin NPH and their randomized bolus insulin.", 
                "measure": "Serum blood glucose area under the curve (AUC) at one 4-hour in-clinic meal challenge", 
                "safety_issue": "No", 
                "time_frame": "week 2 of insulin treatment"
            }, 
            {
                "description": "A1C is measured weekly at each pregnancy visit up to 26 visits.  Subjects are enrolled at 20-32 weeks gestation and have weekly visits to obtain A1C through delivery, and again at the 6-week postpartum visit.", 
                "measure": "Compare A1C at enrollment and weekly until delivery", 
                "safety_issue": "No", 
                "time_frame": "up to 36 weeks"
            }, 
            {
                "description": "Hypoglycemic episodes since the last visit will be reported at each pregnancy visit, usually weekly, from enrollment at 10-30 weeks gestation through delivery and at the 6-week postpartum visit if continuing to take insulin.", 
                "measure": "Compare incidence of hypoglycemic episodes <60 mg/dL with symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "up to 36 weeks"
            }
        ], 
        "source": "Sansum Diabetes Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sansum Diabetes Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}